Clinical Trials · NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Active Not RecruitingN/ASemaglutide (Investigational)Liraglutide (Investigational)Dulaglutide (Investigational)Exenatide (Investigational)Lixisenatide (Investigational)
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 781,430
- Start date
- Aug 2021
- Locations
- 1 site, United States
- Primary endpoint
- MACE